Private Equity Looks To Small, Mid-Size Drug Makers Risking Growth (India)
This article was originally published in PharmAsia News
Executive Summary
Private-equity firms appear increasingly interested in supporting outsourcing ventures among small and mid-size pharmaceutical companies. According to Dr. Sandeep Singhai of Sequoia Capital, that area of drug making is growing faster than growth in the established sectors, so his company is investing in those smaller firms that seek to become major players, despite the added risk of doing so. Another investor notes those types of drug makers already are into contract manufacturing and outsourcing, areas that hold huge potential. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.